DTIL vs. JATT, TIL, CGTX, ATHA, ELUT, GRTS, CVM, PASG, IKNA, and ATRA
Should you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include JATT Acquisition (JATT), Instil Bio (TIL), Cognition Therapeutics (CGTX), Athira Pharma (ATHA), Elutia (ELUT), Gritstone bio (GRTS), CEL-SCI (CVM), Passage Bio (PASG), Ikena Oncology (IKNA), and Atara Biotherapeutics (ATRA). These companies are all part of the "biological products, except diagnostic" industry.
JATT Acquisition (NYSE:JATT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
JATT Acquisition has a net margin of 0.00% compared to JATT Acquisition's net margin of -125.84%. Precision BioSciences' return on equity of -49.58% beat JATT Acquisition's return on equity.
48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 5.1% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Precision BioSciences has a consensus price target of $46.33, suggesting a potential upside of 311.12%. Given JATT Acquisition's higher possible upside, analysts clearly believe Precision BioSciences is more favorable than JATT Acquisition.
Precision BioSciences received 87 more outperform votes than JATT Acquisition when rated by MarketBeat users.
JATT Acquisition has higher earnings, but lower revenue than Precision BioSciences.
In the previous week, Precision BioSciences had 12 more articles in the media than JATT Acquisition. MarketBeat recorded 12 mentions for Precision BioSciences and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.61 beat Precision BioSciences' score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.
Summary
JATT Acquisition and Precision BioSciences tied by winning 6 of the 12 factors compared between the two stocks.
Get Precision BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precision BioSciences Competitors List
Related Companies and Tools
